IPCALAB2023-10-012023-12-31 IPCALAB2023-10-012023-12-31 IPCALAB2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member IPCALAB2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member IPCALAB2023-12-31 IPCALAB2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IPCALAB2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member IPCALAB2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IPCALAB2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member IPCALAB2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member IPCALAB2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524494 IPCALAB NOTLISTED IPCA Laboratories Limited Equity 2023-04-01 2024-03-31 2024-02-14 2024-01-22 INR Crores Third quarter 11:30:00 13:30:00 2024-02-14 2024-02-14 Not applicable Single segment Pharmaceuticals 2023-10-01 2023-12-31 Unaudited Consolidated 20528600000.00 224500000.00 20753100000.00 6099500000.00 1163200000.00 -293200000.00 4590400000.00 334000000.00 995000000.00 5655400000.00 18544300000.00 2208800000.00 680100000.00 2888900000.00 665300000.00 -2900000.00 662400000.00 0.00 2226500000.00 0.00 0.00 0.00 -16500000.00 2210000000.00 10300000.00 2220300000.00 1798800000.00 411200000.00 1816700000.00 403600000.00 253700000.00 1 7.09 7.09 0.00 0.00 7.09 7.09 Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 56720300000.00 1058500000.00 57778800000.00 16512700000.00 3815000000.00 -1429100000.00 12424200000.00 1089000000.00 2591100000.00 15795300000.00 50798200000.00 6980600000.00 680100000.00 7660700000.00 2383600000.00 14100000.00 2397700000.00 0.00 5263000000.00 0.00 0.00 0.00 -47100000.00 5215900000.00 -9700000.00 5206200000.00 4877600000.00 338300000.00 4878400000.00 327800000.00 253700000.00 1 19.23 19.23 0.00 0.00 19.23 19.23 Other Expenses 5655400000.00 Other Expenses 15795300000.00 Actuarial gain/(loss) -3200000.00 Share of OCI from investment in associates -100000.00 Actuarial gain/(loss) -27500000.00 Share of OCI from investment in associates -100000.00 -3300000.00 -27600000.00 -2100000.00 -6400000.00 Exchange difference in translating the financial statement of foreign operation 10500000.00 Exchange difference in translating the financial statement of foreign operation 11000000.00 10500000.00 11000000.00 -1000000.00 -500000.00